The median PFS were 16.2 (95%CI=10.9-21.5) and 14.1 (95%CI=9.0-19.2) months in the HER2-zero and HER2-low breast cancer patients, respectively (P=0.263; Figure 2A). Here, ERBB2 is linked to breast carcinoma.